Five years ago, Eli Lilly and Company $LLY shares were around $166.66 each. As of December 19, 2025, it's closed at $1,071.44—a huge 543% surge fueled by runaway success of weight-loss drugs Mounjaro and Zepbound, plus advancing treatments in diabetes, oncology, and Alzheimer's. Now, look at the one-year chart for the real lesson: Starting January 2025 near $800, it climbed steadily to spring highs around $950, dipped through summer to lows near $700 on market worries or competition fears, then rocketed past $1,000 in fall-winter for a net 34.56% gain. After-hours at $1,071.60 shows the pull, but the rebound highlights strength—with the 52-week high of $1,111.99 already hit and low at $623.78 far below, it's clear short-term dips are just pauses in a powerful uptrend.

Build your portfolio, one day at a time.
Get our daily 5-year horizon picks sent to your inbox. Subscribe here.

The five-year compound annual growth rate (CAGR) is 45.03%, the steady average yearly lift (total growth raised to 1/5 power, minus 1) that rewards backing innovation—about 45% growth per year.

Dollar-cost averaging (DCA) is your prescription: Keep $500 flowing monthly for five years, totaling $30,000. Those summer dips to $700? Perfect chance to buy extra shares cheap, lowering your average cost while peaks like November take smaller portions. From $1,071.44, at a 3.16% monthly growth rate, it all compounds.

In 60 months, your stake could reach $85,622—a $55,622 profit and 185% return. Early investments get the deepest boost, but dip buys like mid-year supercharge the recovery.

The vital message: If you trust Eli Lilly to deliver—launching better drugs, winning approvals, and growing through science breakthroughs—keep investing regularly, no matter short-term drops. In fact, buy more when prices fall, turning those chart valleys into your strongest medicine. Over five years, the odds favor product upgrades and market wins that drive the stock higher.

With a $1.01T market cap, P/E of 52.40 reflecting big bets, and 0.65% dividend yield, your DCA could heal into a robust reward by 2030. Stay the course?